• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Epilepsy - Pipeline Review, H1 2013 Product Image

Epilepsy - Pipeline Review, H1 2013

  • ID: 2497201
  • February 2013
  • 195 pages
  • Global Markets Direct

Epilepsy – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Epilepsy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epilepsy.
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 5
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Epilepsy Overview 9
An Overview of Pipeline Products for Epilepsy 10
Epilepsy Therapeutics under Development by Companies 12
Epilepsy Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Epilepsy Therapeutics – Products under Development by Companies 21
Epilepsy Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Epilepsy Therapeutics Development 26
Kyowa Hakko Kirin Co., Ltd. 26
Neurocrine Biosciences, Inc. 27
Novartis AG 28
Eisai Co., Ltd. 29
H Lundbeck A/S 30
Pfizer Inc. 31
UCB Group 32
Vertex Pharmaceuticals Incorporated 33
Sun Pharmaceutical Industries Limited 34
Aeolus Pharmaceuticals, Inc. 35
GW Pharmaceuticals plc 36
Anavex Life Sciences Corp. 37
Ligand Pharmaceuticals Incorporated 38
Bionomics Limited 39
Neuro-Hitech, Inc. 40
Catalyst Pharmaceutical Partners, Inc. 41
MAP Pharmaceuticals, Inc. 42
CombinatoRx, Incorporated 43
Proximagen Neuroscience plc. 44
NeuroVive Pharmaceutical AB 45
Paloma Pharmaceuticals, Inc. 46
Bio-Link 47
D-Pharm Ltd. 48
Upsher-Smith Laboratories, Inc. 49
Snowdon Inc. 50
BioMAS Ltd. 51
MedGenesis Therapeutix Inc. 52
Celentyx Ltd. 53
Nobelpharma Co., Ltd. 54
Concert Pharmaceuticals, Inc. 55
Biovista Inc. 56
Asklepios BioPharmaceutical, Inc. 57
Marinus Pharmaceuticals, Inc. 58
NeuroTherapeutics Pharma Inc. 59
Bial - Portela & Ca, S.A. 60
Vichem Chemie Research Ltd. 61
FunZyme BioTechnologies S.A. 62
Epilepsy – Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
ANAVEX-2-73 - Drug Profile 68
lacosamide - Drug Profile 69
lacosamide - Drug Profile 73
brivaracetam - Drug Profile 77
perampanel - Drug Profile 79
carbamazepine - Drug Profile 81
ICA-105665 - Drug Profile 83
Antiepileptic Drugs - Drug Profile 85
CSC-700 Series - Drug Profile 86
levetiracetam - Drug Profile 87
diazepam - Drug Profile 90
tonabersat - Drug Profile 91
Dynamin Inhibitors for Epilepsy - Drug Profile 92
NHT-1107 - Drug Profile 94
GWP-42006 - Drug Profile 95
topiramate - Drug Profile 96
ANAVEX-19-144 - Drug Profile 97
belnacasan - Drug Profile 99
GABA-A Agonists - Drug Profile 101
NSD-721 - Drug Profile 102
YKP-3089 - Drug Profile 103
naluzotan - Drug Profile 105
CPP-115 - Drug Profile 106
P-529 - Drug Profile 108
DP-VPA - Drug Profile 110
AS-101 - Drug Profile 112
BGG-492 - Drug Profile 114
liatermin - Drug Profile 116
ganaxolone - Drug Profile 118
fosphenytoin sodium - Drug Profile 120
BVA-601 - Drug Profile 121
Program For Neurological Disorders - Drug Profile 122
topiramate - Drug Profile 123
SUN-44 - Drug Profile 124
AEOL-11207 - Drug Profile 125
eslicarbazepine acetate - Drug Profile 126
C-10068 - Drug Profile 129
everolimus - Drug Profile 131
UCB-0942 - Drug Profile 133
Z-944 - Drug Profile 134
VLB-01 - Drug Profile 135
Drug For Epilepsy - Drug Profile 136
NVP-017 - Drug Profile 137
INS-001 - Drug Profile 139
ABS-103R - Drug Profile 140
VID-45110 - Drug Profile 142
Lanthionine - Drug Profile 143
NTP Compound For Epilepsy - Drug Profile 144
EAB-318 - Drug Profile 145
BNP-TLE - Drug Profile 146
Drug Targeting Kv7.2 And Kv7.3 - Drug Profile 147
SL-327 - Drug Profile 148
GABA Receptor Modulator - Drug Profile 149
Remegal - Drug Profile 150
Gene Therapy For Epilepsy - Drug Profile 151
GABA Agonist - Drug Profile 152
bumetanide - Drug Profile 153
Epilepsy Therapeutics – Drug Profile Updates 154
Epilepsy Therapeutics – Discontinued Products 178
Epilepsy Therapeutics - Dormant Products 179
Epilepsy – Product Development Milestones 182
Featured News & Press Releases 182
Appendix 190
Methodology 190
Coverage 190
Secondary Research 190
Primary Research 190
Expert Panel Validation 190
Contact Us 191
Disclaimer 191

List of Tables
Number of Products Under Development for Epilepsy, H1 2013 14
Products under Development for Epilepsy – Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2013 20
Comparative Analysis by Late Stage Development, H1 2013 21
Comparative Analysis by Mid Clinical Stage Development, H1 2013 22
Comparative Analysis by Early Clinical Stage Development, H1 2013 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Development by Companies, H1 2013 (Contd..1) 26
Products under Development by Companies, H1 2013 (Contd..2) 27
Products under Development by Companies, H1 2013 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2013 29
Kyowa Hakko Kirin Co., Ltd., H1 2013 30
Neurocrine Biosciences, Inc., H1 2013 31
Novartis AG, H1 2013 32
Eisai Co., Ltd., H1 2013 33
H Lundbeck A/S, H1 2013 34
Pfizer Inc., H1 2013 35
UCB Group, H1 2013 36
Vertex Pharmaceuticals Incorporated, H1 2013 37
Sun Pharmaceutical Industries Limited, H1 2013 38
Aeolus Pharmaceuticals, Inc., H1 2013 39
GW Pharmaceuticals plc, H1 2013 40
Anavex Life Sciences Corp., H1 2013 41
Ligand Pharmaceuticals Incorporated, H1 2013 42
Bionomics Limited, H1 2013 43
Neuro-Hitech, Inc., H1 2013 44
Catalyst Pharmaceutical Partners, Inc., H1 2013 45
MAP Pharmaceuticals, Inc., H1 2013 46
CombinatoRx, Incorporated, H1 2013 47
Proximagen Neuroscience plc., H1 2013 48
NeuroVive Pharmaceutical AB, H1 2013 49
Paloma Pharmaceuticals, Inc., H1 2013 50
Bio-Link, H1 2013 51
D-Pharm Ltd., H1 2013 52
Upsher-Smith Laboratories, Inc., H1 2013 53
Snowdon Inc., H1 2013 54
BioMAS Ltd., H1 2013 55
MedGenesis Therapeutix Inc., H1 2013 56
Celentyx Ltd., H1 2013 57
Nobelpharma Co., Ltd., H1 2013 58
Concert Pharmaceuticals, Inc., H1 2013 59
Biovista Inc., H1 2013 60
Asklepios BioPharmaceutical, Inc., H1 2013 61
Marinus Pharmaceuticals, Inc., H1 2013 62
NeuroTherapeutics Pharma Inc., H1 2013 63
Bial - Portela & Ca, S.A., H1 2013 64
Vichem Chemie Research Ltd., H1 2013 65
FunZyme BioTechnologies S.A., H1 2013 66
Assessment by Monotherapy Products, H1 2013 67
Assessment by Stage and Route of Administration, H1 2013 69
Assessment by Stage and Molecule Type, H1 2013 71
Epilepsy Therapeutics – Drug Profile Updates 158
Epilepsy Therapeutics – Discontinued Products 182
Epilepsy Therapeutics – Dormant Products 183
Epilepsy Therapeutics – Dormant Products (Contd..1) 184
Epilepsy Therapeutics – Dormant Products (Contd..2) 185

List of Figures
Number of Products under Development for Epilepsy, H1 2013 14
Products under Development for Epilepsy – Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 20
Late Stage Products, H1 2013 21
Mid Clinical Stage Products, H1 2013 22
Early Clinical Stage Products, H1 2013 23
Discovery and Pre-Clinical Stage Products, H1 2013 24
Assessment by Monotherapy Products, H1 2013 67
Assessment by Route of Administration, H1 2013 68
Assessment by Stage and Route of Administration, H1 2013 69
Assessment by Molecule Type, H1 2013 70
Assessment by Stage and Molecule Type, H1 2013 71

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos